| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 |
| 26 May 2026 |
8-K: Results of Operations and Financial Condition
Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline |
| 20 Apr 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events
The address of the registered office of Kailera Therapeutics, Inc. (the “Corporation”) in the State of Delaware, and the name of its registered agent at such address, shall be as set forth in the Corporation’s certificate of incorporatio... |
Loading...